U.S. markets closed
  • S&P 500

    3,768.47
    -51.25 (-1.34%)
     
  • Dow 30

    30,924.14
    -345.95 (-1.11%)
     
  • Nasdaq

    12,723.47
    -274.28 (-2.11%)
     
  • Russell 2000

    2,146.92
    -60.87 (-2.76%)
     
  • Crude Oil

    64.16
    +0.33 (+0.52%)
     
  • Gold

    1,694.90
    -5.80 (-0.34%)
     
  • Silver

    25.34
    -0.12 (-0.46%)
     
  • EUR/USD

    1.1970
    -0.0097 (-0.80%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • GBP/USD

    1.3892
    -0.0060 (-0.43%)
     
  • USD/JPY

    107.9500
    +0.9480 (+0.89%)
     
  • BTC-USD

    48,231.54
    -2,945.36 (-5.76%)
     
  • CMC Crypto 200

    968.73
    -18.48 (-1.87%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Globus Medical (GMED) Gains From Robot Sales Amid Pandemic Blues

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

On Dec 17, we issued an updated research report on Globus Medical, Inc. GMED. The company continues to witness higher demand for its Musculoskeletal Solutions products. Meanwhile, it is expanding its footprint in the overseas markets by consolidating direct and distributors’ sales force. The stock currently carries a Zacks Rank #3 (Hold).

Over the past three months, shares of Globus Medical have outperformed the industry. The stock has gained 4.5% as compared with 4.3% growth of the sector.

Globus Medical exited the third quarter of 2020 with better-than-expected results despite the pandemic-led business disruptions. The improvement in the company’s U.S. revenues led by the U.S. spine business looks encouraging. Competitive recruiting and onboarding, pull through from a growing base of robotic installations, and impressive uptake from product introductions were all strong contributors to growth.

Globus Medical, Inc. Price

Globus Medical, Inc. Price
Globus Medical, Inc. Price

Globus Medical, Inc. price | Globus Medical, Inc. Quote

Musculoskeletal Solutions increased 14%, led by the U.S. spinal implant business, which grew at 17% during the third quarter. Though revenues from enabling technologies were down $5 million, the same went up 66% sequentially. We are upbeat about the company’s stupendous investments in its R&D wing. Globus Medical launched several products in its spine portfolio, which instills investors’ confidence in the stock.

Meanwhile, the pandemic has wreaked havoc on Globus Medical’s overall business. The business bottomed in mid-April. However, since then there has been a visible rebound in the company’s revenue trend that continued with a steady climb upward through the quarter.

As the economy opened up again in the July-September quarter, the capital teams were able to begin rebuilding pipelines and moving deals along. Many of these deals closed in October, and the company has actually sold more robots in October than it did for all of the September-end quarter.

This growth, according to the company, came on a number of factors, including new product launches, competitive recruiting and robotic pull through.

The company rolled out five new products in 2020 and has seen tremendous uptake in the HEDRON line of 3D printed inner body spacers and its fourth-generation expandable MIS TLIF device. Adoption has been so successful that Globus Medical is currently doubling its 3D manufacturing capacity which would come online in the fourth quarter.

On the flip side, the musculoskeletal devices industry is characterized by an intensifying competitive pricing pressure. Pricing continues to be a major headwind for Globus Medical. Throughout 2019 and till the third quarter of 2020, the company’s top-line growth was partially dampened by the prevailing pricing pressure.

Further, gross margin contractions are worrying. Stiff competition and foreign-exchange impacts are other concerns.

Key Picks

Some better-ranked stocks from the broader medical space are Merit Medical Systems, Inc. MMSI, Align Technology, Inc. ALGN and Thermo Fisher Scientific Inc. TMO, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Merit Medical has a projected long-term earnings growth rate of 12.6%.

Align Technology has an estimated long-term earnings growth rate of 18.3%.

Thermo Fisher has a projected long-term earnings growth rate of 18%.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
 
Align Technology, Inc. (ALGN) : Free Stock Analysis Report
 
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
 
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research